Bladder cancer: Pioglitazone-when is a prescription drug safe?

Yoon Kong Loke; Katharina Mattishent

doi:10.1038/nrurol.2015.237

Bladder cancer: Pioglitazone-when is a prescription drug safe?

Yoon Kong Loke, Katharina Mattishent

Research output: Contribution to journal › Abstract › peer-review

2 Citations (Scopus)

Abstract

In a recent issue of JAMA, Lewis et al. present long-term data on the likelihood of a link between pioglitazone and the risk of bladder cancer and ten other cancers. Their findings contradict previous concerns regarding the safety of pioglitazone, and add to the controversy surrounding interpretation of rare adverse events associated with prescription drugs.

Original language	English
Pages (from-to)	655-656
Number of pages	2
Journal	Nature Reviews Urology
Volume	12
Early online date	29 Sep 2015
DOIs	https://doi.org/10.1038/nrurol.2015.237
Publication status	Published - 2015

Keywords

Bladder cancer
Diabetes
Drug safety

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrurol.2015.237

Cite this

@article{929b0439f4bf4e97b07a80dc2c8272fb,

title = "Bladder cancer: Pioglitazone-when is a prescription drug safe?",

abstract = "In a recent issue of JAMA, Lewis et al. present long-term data on the likelihood of a link between pioglitazone and the risk of bladder cancer and ten other cancers. Their findings contradict previous concerns regarding the safety of pioglitazone, and add to the controversy surrounding interpretation of rare adverse events associated with prescription drugs.",

keywords = "Bladder cancer, Diabetes, Drug safety",

author = "Loke, {Yoon Kong} and Katharina Mattishent",

year = "2015",

doi = "10.1038/nrurol.2015.237",

language = "English",

volume = "12",

pages = "655--656",

journal = "Nature Reviews Urology",